AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Nasdaq

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails  Nasdaq

AbbVie, Inc.ABBV announced that it is discontinuing development of its small-cell lung cancer (SCLC) candidate rovalpituzumab tesirine or Rova-T after failure ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...